Rocuronium for Tracheal Intubation

Authors and Disclosures

If you have any comments, please contact Marcia Buck by mail at Box 274-11, University of Virginia Medical Center, Charlottesville, VA 22908 or by phone (804) 982-0921, fax (804) 982-1682, or e-mail to mlb3u@virginia.edu.

Sidebar

Antiepileptic Review.

A concise, but very interesting review of the impact of physical development on antiepileptic use has been published in a recent supplement to

Pharmacotherapy

. The author addresses the susceptibility of the immature brain, the effects of genetic alterations and perinatal illness, and the impact of maturation on antiepileptic response. Moshe SL. Special considerations in treating children with epilepsy.

Pharmacotherapy 2000:20(8 Pt 2):171S-177S.

The following actions were taken by the Pharmacy and Therapeutics Committee during their meeting on 9/22/00:

1. Quetiapine (Seroquel®) was added to the Formulary for the management of patients with psychotic disorders.

2. Rivastigmine (Exelon®) was added for the management of patients with Alzheimer's disease. Tacrine (Cognex®) was removed from the Formulary.

3. Docetaxel (Taxotere®) was added as a second-line therapy for non-small cell lung cancer and metastatic breast cancer.

4. Gemtuzumab ozogamicin (Mylotarg®) was also added, restricted to use in patients with CD33-positive AML who have relapsed.

5. The following agents were removed from the Formulary because of lack of use: aminophylline tablets, cycloserine capsules, ethionamide tablets, fluoxymesterone, guanethidine tablets, kanamycin capsules, metaproterenol tablets, metocurine injection, methoxamine injection, methysergide tablets, norethynodrel/mestranol tablets, and xylometazoline for intranasal use.